Ann: Imugene HER-Vaxx Phase 2 PFS Data and Flags Three New Trials, page-105

For anybody that still has doubts about HER-Vaxx, or Imugene's B Cell platform, today's news should put to rest once and for all any doubts.

People, its very very simple!!!!! If HER-Vaxx didn't work, Imugene would announce that all further trials have been terminated, disband all test centers, and advise patients (& the market) that the vaccine didn't demonstrate any benefit.

But what did today's announcement actually say - that Imugene is so confident with the HER-Vaxx vaccine, and the results to date are so encouraging that they are now going to proceed with 3 (Yes, 3 !!!!!!) new trials.

Read the actual announcement :
"Imugene’s PFS HR was comparable to the landmark Genentech/Roche registrational ToGA study (PFS HR of 0.71), which also examined the effect of Herceptin plus chemotherapy versus SOC chemotherapy alone in advanced HER-2 positive gastric cancer.

Based on these results, Imugene now plans two further company sponsored Phase 2 studies and one Investigator Sponsored Study with HER-Vaxx in early and late stage gastric cancer."